Key result
Olanzapine monotherapy linked to ~8 kg weight gain and adverse metabolic changes in psychotic disorders.
Why the study?
The study evaluated the impact of olanzapine on metabolic changes in patients with psychotic disorders.
Does olanzapine monotherapy worsen metabolic parameters and cardiovascular risk factors in patients with psychotic disorders?
Population
253 patients with psychotic disorders prescribed olanzapine in Oman
Comparison
Metabolic and cardiovascular changes associated with olanzapine monotherapy
Design
Retrospective cohort study
Authors
Loading...
May warrant metabolic monitoring with olanzapine; leaves open effects on cardiovascular events versus alternatives.
Cohort (n=253)
No
Does olanzapine monotherapy worsen metabolic parameters and cardiovascular risk factors in patients with psychotic disorders?
Effect estimate: +8 kg (95% CI 6-9)
p-value: p=<.001
Olanzapine monotherapy in patients with psychotic disorders is associated with significant adverse metabolic changes, leading to suboptimal attainment of cardiovascular risk factor targets.
Al-Tobi et al. (2022) conducted a cohort in psychotic disorders (n=253). olanzapine was evaluated on body weight change (+8 kg, 95% CI 6-9, p=<.001). Olanzapine monotherapy in patients with psychotic disorders was associated with increased body weight (+8 kg; 95% CI: 6-9; P<.001) and other adverse metabolic changes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: